(Q38005887)

26 August 2017

Angiogenesis in neuroendocrine tumors: therapeutic applications (English)

1 reference

26 August 2017

1 reference

1

Jean-Yves Scoazec

0 references

publication date

7 June 2012

1 reference

26 August 2017

1 reference

26 August 2017

97

1 reference

26 August 2017

1

1 reference

26 August 2017

45-56

1 reference

Tumour vascularization: sprouting angiogenesis and beyond

26 August 2017

1 reference

Mechanisms of resistance to antiangiogenesis therapy

21 January 2018

1 reference

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

21 January 2018

1 reference

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

Chemokines in tumor angiogenesis and metastasis

21 January 2018

1 reference

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

21 January 2018

1 reference

VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

Microvascular development: learning from pancreatic islets

21 January 2018

1 reference

The vascular niche and its basement membrane.

21 January 2018

1 reference

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models

21 January 2018

1 reference

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors

21 January 2018

1 reference

Angiogenesis and tumor progression in neuroendocrine digestive tumors

21 January 2018

1 reference

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids.

21 January 2018

1 reference

Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis.

21 January 2018

1 reference

Microvessel density in pituitary adenomas and carcinomas

21 January 2018

1 reference

Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes.

21 January 2018

1 reference

Angiogenesis in endocrine tumors.

21 January 2018

1 reference

The role of angiogenesis in endocrine liver metastases: an experimental study

21 January 2018

1 reference

The effects of the somatostatin analog octreotide on angiogenesis in vitro.

21 January 2018

1 reference

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action

21 January 2018

1 reference

Effects of somatostatin and octreotide on the interactions between neoplastic gastroenteropancreatic endocrine cells and endothelial cells: a comparison between in vitro and in vivo properties

21 January 2018

1 reference

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

21 January 2018

1 reference

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

Current status of angiogenesis inhibitors combined with radiation therapy

21 January 2018

1 reference

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies

21 January 2018

1 reference

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

21 January 2018

1 reference

Vascular disrupting agents: a new class of drug in cancer therapy

21 January 2018

1 reference

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

21 January 2018

1 reference

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

21 January 2018

1 reference

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

21 January 2018

1 reference

An overview of small-molecule inhibitors of VEGFR signaling

21 January 2018

1 reference

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation.

21 January 2018

1 reference

Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

21 January 2018

1 reference

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

21 January 2018

1 reference

Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro

21 January 2018

1 reference

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth

21 January 2018

1 reference

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

21 January 2018

1 reference

Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors

21 January 2018

1 reference

Pharmacogenetics in chemotherapy of colorectal cancer

21 January 2018

1 reference

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

21 January 2018

1 reference

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

21 January 2018

1 reference

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates

21 January 2018

1 reference

The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors

21 January 2018

1 reference

Angiopoietin-2 promotes disease progression of neuroendocrine tumors

21 January 2018

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model

21 January 2018

1 reference

Consice review: Contribution of cancer stem cells to neovascularization

21 January 2018

1 reference

Cancer stem cells switch on tumor neovascularization

21 January 2018

1 reference

Contribution of cancer stem cells to tumor vasculogenic mimicry

21 January 2018

1 reference

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 January 2018

1 reference

Clinical biomarkers of angiogenesis inhibition

21 January 2018

1 reference

The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis

21 January 2018

1 reference

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

21 January 2018

1 reference

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose

21 January 2018

1 reference

Biomarkers for monitoring antiangiogenic therapy

21 January 2018

1 reference

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

21 January 2018

1 reference

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

21 January 2018

1 reference

The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials

21 January 2018

1 reference

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

21 January 2018

1 reference

Molecular and cellular biomarkers for angiogenesis in clinical oncology

21 January 2018

1 reference

Anti-VEGF therapy: the search for clinical biomarkers

21 January 2018

1 reference

How molecular imaging is speeding up antiangiogenic drug development

21 January 2018

1 reference

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

21 January 2018

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

21 January 2018

1 reference

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

21 January 2018

1 reference

Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors

21 January 2018

1 reference

Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000338371

1 reference

26 August 2017

1 reference

PubMed ID

22538258